Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (Japan) holds 3 active US FDA Type II Drug Master Files and 3 inactive, has DMF or CEP filings on record for 4 active ingredients and is linked to 3 FDA-registered manufacturing sites. 17 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Takeda Pharmaceutical Company Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/takeda-pharmaceutical-company-limited

Overview

Takeda Pharmaceutical Company Limited is a leading global biopharmaceutical company, focusing on innovative medicines and vaccines. Takeda operates in various therapeutic areas, leveraging its expertise to improve health and offer treatments that change lives. As of 2016, it acquired Baxalta Incorporated, expanding its robust portfolio. Takeda is the parent company, with Baxalta now integrated into its operations.

Core services & business areas

Pharmaceutical ManufacturingQuality AssuranceResearch and DevelopmentPharmaceutical ResearchDrug DevelopmentRegulatory AffairsSales and Marketing

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Takeda Pharmaceutical Company Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Takeda Pharmaceutical Company Limited holds 3 active (6 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • TAP-144-SR (1M)Active1995-03-24
  • LEUPROLIDE ACETATEActive1993-08-13
  • TAP-144-SR (3M) (22.5MG.)Active1991-09-30
  • HYDROMORPHONE HYDROCHLORIDEInactive1987-07-13
  • LUPRON DEPOT AND LUPRON DEPOT VEHICLEInactive1987-06-09
  • FOLIC ACIDInactive1974-08-23

Registered manufacturing sites (3)

Physical sites registered with the US FDA and resolved to Takeda Pharmaceutical Company Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

17 FDA enforcement records linked to this company.

  • warning_letter2020-06-10

    FDA Warning Letter (drug product)

  • 4832019-11-26

    Validation lacking for sterile drug products

  • 4832019-11-26

    Cleaning / Sanitizing / Maintenance

  • 4832019-11-26

    Failing drug products not rejected

  • 4832019-11-26

    Extent of discrepancy, failure investigations

  • 4832019-11-26

    Procedures for sterile drug products

  • 4832019-11-26

    Written procedures fail to include

  • 4832019-11-26

    Procedures not in writing, fully followed

  • 4832019-08-09

    Validation lacking for sterile drug products

  • 4832019-08-09

    Procedure Deviations Recorded and Justified

  • 4832019-08-09

    Scientifically sound laboratory controls

  • 4832019-08-09

    Complete test data included in records

  • 4832013-09-06

    Test methods

  • 4832013-09-06

    Investigations of discrepancies, failures

  • 4832013-09-06

    Control procedures to monitor and validate performance

  • 4832013-09-06

    Procedures for sterile drug products

  • 4832013-09-06

    Procedures not in writing, fully followed

For suppliers

Is this Takeda Pharmaceutical Company Limited?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.